Novo Nordisk receives subpoena in the US (16 February 2011)

Novo Nordisk receives subpoena in the US (16 February 2011)
 Read in PDF format
The office of the US Attorney for the District of Massachusetts has served Novo Nordisk with a subpoena calling for the production of documents regarding potential criminal offences relating to the company's marketing and promotion practices for the following products:  NovoLog® , Levemir®, and Victoza®. Novo Nordisk will cooperate with the US Attorney in this investigation.

At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information.

Further information:

Media:  Investors: 

Rachel Curtis Graversen  Klaus Bülow Davidsen 
Tel: (+45) 4442 7603  Tel: (+45) 4442 3176 
[email protected]  [email protected]


 Kasper Roseeuw Poulsen 

 Tel: (+45) 4442 4471 

 [email protected] 


 Jannick Lindegaard 

 Tel: (+45) 4442 4765 

 [email protected] 

In North America:  In North America 
Ken Inchausti  Hans Rommer 
Tel: (+1) 609 786 8316  Tel: (+1) 609 919 7937 
[email protected]   [email protected] 


Company Announcement no 10 / 2011

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.